TG THERAPEUTICS, INC.
Company Stats
- Market Cap
- $8.5B
- as of Sep 30, 2026
- Shares Outstanding
- 153.1M
- Free Float
- 78.9%
Income Statement
- Revenue
- $616.3M
- Operating Income
- $123.3M
- Net Income
- $447.2M
- EBITDA
- $123.4M
- Revenue Growth, 3Y
- 504.9%
- FCF Margin, 3Y Avg
- -9.9%
- FCF Margin, Worst Year
- -13.4%
Cash Flow
- Free Cash Flow
- -$25.0M
- FCF Yield
- -0.3%
- Owner FCF Yield
- -1.1%
Balance Sheet
- Cash & Equivalents
- $79.1M
Returns & Capital
- Share Repurchases
- $91.2M
- Buyback Yield, 3Y Avg
- 0.4%
- SBC, 3Y Avg
- $48.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $616.3M | -$25.0M | -4.1% |
| FY2024 | $329.0M | -$40.6M | -12.3% |
| FY2023 | $233.7M | -$31.4M | -13.4% |
| FY2022 | $2.8M | -$176.2M | -6326.2% |
| FY2021 | $6.7M | -$296.0M | -4425.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 9, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back